ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

FDA Strengthens Warning Label for Certain Antiinflammatory Drugs

Reuters Staff  |  July 14, 2015

(Reuters)—The U.S. Food and Drug Administration is strengthening an existing warning label that non-aspirin, non-steroidal antiinflammatory drugs (NSAIDs) increase the risk of heart attack or stroke. NSAIDs include ibuprofen, naproxen, diclofenac and celecoxib, all of which carry FDA warning labels. The agency said it would require updates to the labels of prescription and over-the-counter (OTC)…

CMS Acts on the ACR’s Requests & Announces ICD-10 Grace Period

Will Harvey  |  July 14, 2015

In a win for the ACR and rheumatologists, for one year after the mandatory ICD-10 implementation on Oct. 1, 2015, CMS will not deny claims on the basis of incorrect ICD-10 sub-codes.

White House Is Open to Working with Congress on Disease Research Bill

Reuters Staff  |  July 13, 2015

WASHINGTON (Reuters)—The White House said on Wednesday it was open to working with Congress on a bill that would invest in disease research and would be paid for with sales of oil from U.S. emergency reserves. The House of Representatives is considering a bipartisan bill that would increase funding for the U.S. National Institutes of…

Studies Challenge Conventional Infliximab Protocols in IBD

Laura Newman  |  July 10, 2015

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. “Patients with ulcerative…

Knee Surgery for Pain May Not Be Worthwhile

Lisa Rapaport  |  July 9, 2015

(Reuters Health)—Middle-aged and older adults with torn cartilage or painful arthritis in their knee are not likely to benefit from arthroscopic surgery, and could be harmed by it, a review of past studies hints. Researchers reviewed nine previous studies with a combined 1,270 patients and found the surgery no better than other options like exercise…

Second Indian Firm Under Fire for Shoddy Clinical Drug Trials

Ben Hirschler & Zeba Siddiqui  |  July 8, 2015

LONDON/MUMBAI (Reuters)—Another Indian clinical research organization, Quest Life Sciences of Chennai, is in trouble over defective trials work, according to a warning issued by the World Health Organization. The action by the United Nations health agency follows an earlier scandal over drug testing at GVK Biosciences, which resulted in approvals for hundreds of generic drugs…

Many Healthcare Providers Come to Work Sick

Kathryn Doyle  |  July 7, 2015

(Reuters Health)—Many doctors, nurses, midwives and physician assistants come to work sick even though they know it puts patients at risk, a new survey hints. Many said they don’t call in sick because they don’t want to let colleagues or patients down by taking a sick day, and they were concerned about finding staff to…

Rheumatology Community Applauds CMS Guidance Providing ICD-10 “Safe Harbor” Period, Encourages Further Action to Ensure Responsible Transition

American College of Rheumatology  |  July 7, 2015

ATLANTA, Ga.—The American College of Rheumatology (ACR) today praised the Centers for Medicare and Medicaid Services (CMS) for issuing new guidance to provide a 12-month “safe harbor” period for physicians following the Oct. 1 implementation of the ICD-10 code set. The ACR has led legislative and grassroots efforts to responsibly address the transition to the…

E-Learning in Physiotherapy

Arthritis Care & Research  |  July 7, 2015

A physiotherapy-specific, Web-based e-learning platform, “RAP-el,” was studied to determine its effectiveness in assisting physiotherapists with the best-practice management of rheumatoid arthritis (RA). It was shown to improve self-reported confidence, likely practice behaviors and satisfaction in physiotherapists’ ability to manage people with RA, and improve their clinical knowledge in several areas…

After Default, Fight Breaks Out Over Greek Medicine Supplies

Ben Hirschler  |  July 6, 2015

LONDON (Reuters)—Wholesalers trading medicines across European borders have criticized a suggestion by manufacturers that Greek exports should be restricted to prevent shortages of life-saving drugs in the country. Such trade, which allows traders to buy products in low-cost markets and sell them where prices are higher, is allowed under EU free trade rules. But drugmakers…

  • « Previous Page
  • 1
  • …
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences